Combretastatin A4 phosphate disodium CAS 168555-66-6

Combretastatin A4 Phosphate Disodium (CAS 168555-66-6) User Guide

Table of Contents

• 1. Product Overview & Specifications
• 2. Applications & Mechanisms of Action
• 3. Usage Guidelines & Best Practices
• 4. Case Studies
• 5. Client Success Stories
• 6. Request Customized Solutions

1. Product Overview & Specifications

2. Applications & Mechanisms of Action

Primary Therapeutic Applications:

• Solid tumor vasculature disruption
• Adjuvant therapy for radioresistant cancers
• Combination therapy with angiogenesis inhibitors

Mechanistic Advantages:

• Binds β-tubulin at colchicine site (Kd = 0.4 μM)
• Induces rapid tumor endothelial cell apoptosis
• Reduces tumor blood flow within 1-6 hours

3. Usage Guidelines & Best Practices

Recommended Protocols:

4. Case Studies

Study 1: Triple-Negative Breast Cancer

• 68% reduction in tumor volume (vs control)
• Synergy observed with paclitaxel (CI=0.32)

Study 2: Hepatocellular Carcinoma

• 54% decrease in tumor perfusion (DCE-MRI)
• Enhanced sorafenib penetration (3.2x increase)

5. Client Success Stories

PharmaCorp Oncology:
Achieved Phase II clinical endpoints using 100 mg/m² dosing regimen with 40% partial response rate in anaplastic thyroid cancer.

University Research Team:
Published in Cancer Research (IF: 13.312) demonstrating tumor-selective vascular collapse within 4 hours post-administration.

6. Request Customized Solutions

Contact our technical specialists for:

• Bulk API synthesis (GMP-grade available)
• Custom formulation development
• Preclinical study design support

Email: info@vivalr.com
Phone: (86) 15866781826